Nathan J. Alves, PhD
Associate Professor of Emergency Medicine
Adjunct Associate Professor of Anatomy, Cell Biology & Physiology
Adjunct Associate Professor of Biochemistry & Molecular Biology
Director of Translational Research, Emergency Medicine
Research Director, Emergency Medicine
Associate Professor of Biomedical Engineering, Purdue University
- Phone
- (317) 278-3828
- Address
-
FT FOB 3rd Floor
EMER
IN
Indianapolis, IN - PubMed:
-
Bio
Dr. Nathan J. Alves received his PhD in Chemical and Biomolecular Engineering from the University of Notre Dame. Following graduate school, he completed a post-doctoral research fellowship at the IU School of Medicine, where he began his work on the pharmaceutical delivery of clot-digesting enzymes utilizing a nanoparticle-based delivery system. He then spent two years at the Naval Research Laboratory (NRL) in DC on a National Academy of Science Research Associateship. Currently, Dr. Alves is the Director of Translational Research and an Associate Professor at the Indiana University School of Medicine (IUSM) in the Department of Emergency Medicine with a joint appointment at Purdue University in Biomedical Engineering. The research he conducts, while spanning many disciplines, is centered on the development of translational technologies, treatments, and techniques that can be utilized to have a positive impact on people’s lives. He has extensive experience in: nanoparticle drug delivery, packaging of pharmaceutical agents/enzymes to treat various diseases, studying the effect that microplastic exposure has on coagulation and fibrinolysis, site-specific antibody modification, oriented antibody immobilization for advanced diagnostics, and extracellular vesicles (EV). His multidisciplinary background affords him a unique perspective to tackle complex therapeutic and medical device development problems.
Key Publications
- Zeng Z., Christodoulides A., Alves N. J. (2023). Real-time Tracking of Fibrinolysis Under Constant Wall Shear and Various Pulsatile Flows in an in-vitro Thrombolysis Model. Bioengineering & Translational Medicine, e10511, doi:10.1002/btm2.10511.
- Nallan Chakravarthula T., Zeng Z., Alves N. J. (2022). Multivalent Benzamidine Molecules for Plasmin Inhibition: Effect of Valency and Linker Length. ChemMedChem, 17(22), e202200364.
- Zeng Z., Chakravarthula T. N., Muralidharan C., Hall A., Linnemann A. K., Alves, N. J. (2021). A Unique Fluorescently Labeled Annular Clot Lysis Assay for Diagnostic and Drug Development Applications. Royal Society of Chemistry: Journal of Materials Chemistry B, 9(45), 9295-9307.~featured on cover.
- Lett Z., Hall A., Skidmore S., Alves N. J. (2021). Environmental Microplastic and Nanoplastic: Exposure Routes and Effects on Coagulation and the Cardiovascular System. Environmental Pollution, 291, 118190.
- Alves, N. J., Turner, K. B., Daniele, M. A., Oh, E., Medintz, I. L., & Walper, S. A. (2015). Bacterial Nanobioreactors-Directing Enzyme Packaging into Bacterial Outer Membrane Vesicles. ACS Applied Materials & Interfaces, 7(44), 24963-24972.
- Alves N. J., Mustafaoglu N., Bilgicer B. (2013). Oriented antibody immobilization by site-specific UV photocrosslinking of biotin at the conserved nucleotide binding site for enhanced antigen detection. Biosensors and Bioelectronics, 49, 387-393.
- Paraskar A.S., Son, S., Chin K.T., Chaudhuri P., Muto K.W., Berkowitz J., Handlogten M.W., Alves N.J., Bilgicer B., Dinulescu D.M., Mashelkar R.A. (2010). Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proceedings of the National Academy of Sciences, 107(28), pp.12435-12440.
| Year | Degree | Institution |
|---|---|---|
| 2013 | PhD | University of Notre Dame |
| 2011 | MS | University of Notre Dame |
| 2008 | MS | University of Rochester |
| 2007 | BS | University of Rochester |
As a chemical and biomolecular engineer, I love conducting research at the interface of science, engineering, and medicine. I am particularly driven to develop translational solutions to real-world clinical problems. This goal is achieved through collaborative research initiates, publication, and patent filings. The following are my areas of active interest:
-Developing safter direct fibrinolytic therapeutics to effectively digest blood clots while limiting bleeding risk.
-Creating high fidelity in-vivo like blood clots with reproducible clot architecture.
-Establish an ex-vivo testing platform for assessing novel clot digesting therapeutics under flow at physiologically relevant length scales.
-Identify how multivalency can be leveraged to modulate enzyme activity in the body.
-Studying the effects of microplastic and nanoplastic exposure on coagulation and fibrinolysis through various routes of exposure.
Desc: Trustee Teaching Award
Scope: University
Date: 2024-04-01
Desc: Inaugural 23 PAIR (Promising Achiever in Innovation and Research) Recipient
Scope: State
Date: 2022-03-01
Desc: Translating Research into Practice (TRIP) Scholar
Scope: Campus
Date: 2017-01-01
Desc: National Research Council (NRC) Post-Doctoral Research Associateship
Scope: National
Date: 2014-01-01
Desc: Baxter Young Investigator Award as an Up-and-Coming Mind in Science
Scope: National
Date: 2013-01-01
Desc: John H. Wallace Diversity Fellow
Scope: Regional
Date: 2013-01-01
Desc: Notebaert Professional Development Grant
Scope: Campus
Date: 2012-01-01